To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone, and for other purposes.
This bill would overturn changes the Food and Drug Administration made to mifepristone's safety requirements in January 2023. Mifepristone is a medication used for medical abortion. The FDA's 2023 changes relaxed restrictions on how the drug could be prescribed and distributed, including allowing it to be dispensed by mail. This legislation would reverse those changes and prohibit the federal government from spending any money to implement or enforce the FDA's modified safety rules for the drug. The bill would also prevent the FDA from using enforcement discretion to allow the more lenient requirements to continue in practice. The measure was introduced in September 2023 and referred to the House Energy and Commerce Committee.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.